Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System.

ABSTRACT:

Importance

In early 2018, durvalumab became the first immunotherapy to be approved for adjuvant treatment of patients with unresectable stage III non-small cell lung cancer (NSCLC) whose cancer has not progressed after definitive chemoradiotherapy. However, the cost-effectiveness and potential economic implications of using this high-priced therapy in this indication are unknown to date.

Objective

To explore the cost-effectiveness and potential budgetary consequences of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III NSCLC in the context of the US health care system.

Design, setting, and participants

A decision analytic microsimulation model was developed in an academic medical setting to compare the following 2 postch

SUBMITTER: Criss SD 

PROVIDER: S-EPMC6439842 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature